Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Right after Robert F. Kennedy Jr. secured confirmation as U.S. | The Department of Health and Human Services has removed all ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

A new era of hypertension treatment is on the horizon for U.S. | The drug is the first triple-combo pill for the initial ...

Before joining Priovant, the new Abcuro executive spent more than a decade at Genzyme before its acquisition by Sanofi, ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Despite some recent setbacks to its sickle cell disease (SCD) pipeline, Pfizer is plowing ahead in improving education around ...

Rechon Life Sciences, a Sweden-based pharma contract manufacturer, was hit with a warning letter from the FDA following an ...

After delivering strong sales growth last year and with more expansion in mind, CDMO giant Wuxi Biologics is breaking ground ...

As radiopharmaceutical therapies gain momentum, new challenges are emerging in how they’re administered—especially around ...

After two years of quietly shifting its medical affairs and commercial strategy units under one roof, Astellas is entering a ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...